The World Leader in Serving Science April 2004 Safe Harbor Statement Fisher at a Glance Market Dynamics are Favorable Company Capabilities Key Strategies Improved Product Mix Apogent Transaction Rationale Sales Growth Earnings Per Share Growth Strong Operating Cash Flow Summary of Guidance Investmen
Slide 2: Safe Harbor Statement
This presentation contains statements that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on Fisher's and Apogent's current expectations and beliefs and are subject to a number of risks, uncertainties and a
Slide 3: Fisher at a Glance
Fisher at a Glance - Founded in 1902 Proprietary 60% Distributed 40% 80% Consumable * Midpoint of management estimates and includes effect of the Apogent transaction. 350,000 customers Global scientific research $20 U.S. clinical laboratory $10 2004E* Sales $4.6B EPS $2.81 Growing Markets ($ Bils) F
Slide 4: Market Dynamics are Favorable
7 Scientific Research 75% Clinical Lab 25% No Customer > 2.5% of Sales Market Dynamics are Favorable Pharma 0.23 Hospitals 0.17 Reference Labs / Other 0.08 Other 0.33 Medical Research 0.08 Colleges and Universities 0.11 Pressure on drug development costs Aging population R&D spending steadily increa
Slide 5: Company Capabilities
The Fisher brand Global logistics Industry-leading sales force Sales reps 1,500 Technical specialists 800 Customer service reps 1,200 Company Capabilities
Slide 6: Key Strategies
Key Strategies Increase proprietary product and service offering to enhance margins Capitalize on high growth life science footprint to accelerate revenue growth Pursue promising acquisition candidates Increase earnings and cash flow Apogent - A perfect fit 11
Slide 7: Improved Product Mix
Improved Product Mix Life Science Products 0.33 Scientific Research Products 0.18 Other Equipment 0.17 Clinical Lab Products 0.32 Based on pro forma 2004 sales Life Science Products 0.18 Scientific Research Products 0.55 Lab Workstations 0.09 Clinical Lab Products 0.23 Pro forma 2004 sales $5 billio
Slide 8: Apogent Transaction Rationale
Apogent Transaction Rationale Enhances portfolio of proprietary products and services Increases Fisher's life science footprint to $1.1 billion Strengthens Fisher's healthcare business Provides significant cost savings opportunities Increases cash flow generation 15
Slide 9: Sales Growth
Sales Growth ($ in Billions) 2000 2001 2002 2003 2004F* 2005F* *Midpoint of management estimates and assumes Apogent transaction closes in early 3rd quarter, 2004. Excludes the impact of foreign exchange. CAGR: 16%
Slide 10: Earnings Per Share Growth
Earnings Per Share Growth ($ in Millions) 2000 2001 2002 2003 2004F* 2005F* Excludes goodwill amortization, restructuring and nonrecurring expenses. * Midpoint of management estimates and assumes Apogent transaction closes in early 3rd quarter, 2004. Excludes the effect of conversion of contingent c
Slide 11: Strong Operating Cash Flow
Strong Operating Cash Flow 2000 2001 2002 2003 2004F 2005F ($ in millions) Free cash flow is cash from operations less capital expenditures. * Midpoint of management estimates and assumes Apogent transaction closes in early 3rd quarter, 2004. Memo: Free Cash Flow $78 $119 $115 $138 $215 $395 * *
Slide 12: Summary of Guidance
Summary of Guidance Note: Excludes goodwill amortization, restructuring and nonrecurring expenses and related charges. $ in millions, except EPS
Slide 13: Investment Highlights
Investment Highlights Strong earnings and cash flow growth Favorable market dynamics Significant margin enhancement opportunities Strong management team
Slide 14: The World Leader in Serving Science
The World Leader in Serving Science
Slide 15: Additional Information About the Merger
In connection with the proposed merger, Fisher Scientific and Apogent Technologies will file relevant materials with the SEC, including one or more registration statement(s) that contain a prospectus and a joint proxy statement, including one that was filed on April 16, 2004. Investors and security
Source: SEC EDGAR · 425 filed Apr 20, 2004
More decks from Fisher Scientific International Inc